Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotech company developing novel immunotherapies for cancer treatment, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. CEO Robert Connelly will present on September 11, 2024, at 2:30 p.m. ET. The presentation will be available via live webcast and on-demand for 90 days afterward.
Elicio specializes in lymph node-targeted immunotherapies using their proprietary AMP technology. This approach aims to enhance the immune system's cancer-fighting capabilities by delivering therapeutic payloads directly to lymph nodes. Their R&D pipeline includes off-the-shelf therapeutic cancer vaccines ELI-002 (for mKRAS-driven cancers), ELI-007, and ELI-008 (for BRAF-driven cancers and p53 hotspot mutations, respectively).
Elicio Therapeutics (Nasdaq: ELTX), una compagnia biotech in fase clinica che sviluppa nuove immunoterapie per il trattamento del cancro, ha annunciato la sua partecipazione alla 26ª Conferenza Annuale Globale sugli Investimenti H.C. Wainwright. Il CEO Robert Connelly presenterà il 11 settembre 2024, alle 14:30 ET. La presentazione sarà disponibile tramite webcast dal vivo e on-demand per 90 giorni successivi.
Elicio è specializzata in immunoterapie mirate ai linfonodi utilizzando la loro tecnologia AMP proprietaria. Questo approccio mira a potenziare le capacità del sistema immunitario nella lotta contro il cancro, consegnando carichi terapeutici direttamente ai linfonodi. Il loro pipeline di ricerca e sviluppo include vaccini terapeutici per il cancro pronti all'uso ELI-002 (per i tumori a guida mKRAS), ELI-007 e ELI-008 (rispettivamente per i tumori a guida BRAF e per le mutazioni hotspot p53).
Elicio Therapeutics (Nasdaq: ELTX), una compañía biotecnológica en etapa clínica que desarrolla nuevas inmunoterapias para el tratamiento del cáncer, anunció su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El CEO Robert Connelly presentará el 11 de septiembre de 2024, a las 2:30 p.m. ET. La presentación estará disponible a través de una transmisión en vivo y bajo demanda durante 90 días después.
Elicio se especializa en inmunoterapias dirigidas a los ganglios linfáticos utilizando su tecnología AMP patentada. Este enfoque tiene como objetivo potenciar las capacidades del sistema inmunológico para combatir el cáncer mediante la entrega de cargas terapéuticas directamente a los ganglios linfáticos. Su pipeline de investigación y desarrollo incluye vacunas terapéuticas para el cáncer listas para usar ELI-002 (para cánceres impulsados por mKRAS), ELI-007 y ELI-008 (para cánceres impulsados por BRAF y mutaciones hotspot p53, respectivamente).
Elicio Therapeutics (Nasdaq: ELTX)는 암 치료를 위한 혁신적인 면역 치료제를 개발하는 임상 단계의 생명공학 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. CEO 로버트 코넬리는 2024년 9월 11일 오후 2:30 ET에 발표를 할 예정입니다. 발표는 생방송 웹캐스트와 이후 90일 간 온디맨드로 제공됩니다.
Elicio는 자사의 독점 AMP 기술을 활용하여 림프절 목표 면역 치료제를 전문으로 합니다. 이 접근 방식은 치료적 화물을 림프절에 직접 전달하여 면역 체계의 암 퇴치 능력을 향상시키는 것을 목표로 합니다. 그들의 연구 개발 파이프라인에는 준비된 치료 암 백신 ELI-002 (mKRAS 유도 암에 대한), ELI-007, ELI-008 (각각 BRAF 유도 암과 p53 핫스팟 변이에 대한)가 포함됩니다.
Elicio Therapeutics (Nasdaq: ELTX), une entreprise biopharmaceutique en phase clinique développant de nouvelles immunothérapies pour le traitement du cancer, a annoncé sa participation à la 26e Conférence Annuelle Mondiale des Investissements H.C. Wainwright. Le PDG Robert Connelly présentera le 11 septembre 2024 à 14h30 ET. La présentation sera disponible via un webinaire en direct et à la demande pendant 90 jours après.
Elicio se spécialise dans les immunothérapies ciblées sur les ganglions lymphatiques en utilisant leur technologie exclusive AMP. Cette approche vise à améliorer les capacités du système immunitaire à lutter contre le cancer en livrant des charges thérapeutiques directement aux ganglions lymphatiques. Leur pipeline de recherche et développement inclut des vaccins thérapeutiques anticancéreux prêts à l'emploi ELI-002 (pour les cancers à l'origine mKRAS), ELI-007 et ELI-008 (pour les cancers à l'origine BRAF et les mutations hotspot de p53, respectivement).
Elicio Therapeutics (Nasdaq: ELTX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das neuartige Immuntherapien zur Krebsbehandlung entwickelt, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright angekündigt. CEO Robert Connelly wird am 11. September 2024 um 14:30 Uhr ET präsentieren. Die Präsentation wird über einen Live-Webcast und 90 Tage lang auf Abruf verfügbar sein.
Elicio spezialisiert sich auf immuntherapeutische Ansätze, die auf Lymphknoten abzielen, wobei sie ihre proprietäre AMP-Technologie nutzen. Dieser Ansatz zielt darauf ab, die Fähigkeit des Immunsystems zur Bekämpfung von Krebs zu verbessern, indem therapeutische Wirkstoffe direkt an die Lymphknoten abgegeben werden. Ihre F&E-Pipeline umfasst einsatzbereite therapeutische Krebsimpfstoffe ELI-002 (für mKRAS-getriebene Krebserkrankungen), ELI-007 und ELI-008 (für BRAF-getriebene Krebserkrankungen und p53-Hotspot-Mutationen).
- None.
- None.
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 2:30 p.m. ET.
A live webcast of the presentation will be accessible to registered attendees via Elicio’s Events page. An archived replay will be available on-demand for 90 days following the event.
About Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers. By combining expertise in immunology and immunotherapy, Elicio is harnessing the natural power of the immune system with the AMP technology, which allows for therapeutic payloads to be delivered directly to the lymph nodes, with the goal of enhancing the immune system’s cancer-fighting capabilities. By targeting cancer immunotherapies to the core of the immune response, AMP aims to optimize the lymph nodes’ natural ability to educate, activate and amplify cancer-specific T cells, which are essential for recognizing and eliminating tumor cells. Engineered to synchronize immunity in these highly potent sites, AMP is built to enhance the magnitude, potency, quality and durability of the immune response to drive antitumor activity. Elicio’s R&D pipeline includes off-the-shelf therapeutic cancer vaccines ELI-002, (targeting mKRAS-driven cancers) as well as ELI-007 and ELI-008 (targeting BRAF-driven cancers and p53 hotspot mutations, respectively). For more information, please visit www.elicio.com.
Investor Relations Contact
Brian Piekos
Elicio Therapeutics
IR@elicio.com
857-209-0153
FAQ
When is Elicio Therapeutics (ELTX) presenting at the H.C. Wainwright Global Investment Conference?
What is the focus of Elicio Therapeutics' (ELTX) research and development?
What cancer vaccines are in Elicio Therapeutics' (ELTX) R&D pipeline?
How can investors access Elicio Therapeutics' (ELTX) presentation at the H.C. Wainwright conference?
